JP2020114855A5 - - Google Patents

Download PDF

Info

Publication number
JP2020114855A5
JP2020114855A5 JP2020065498A JP2020065498A JP2020114855A5 JP 2020114855 A5 JP2020114855 A5 JP 2020114855A5 JP 2020065498 A JP2020065498 A JP 2020065498A JP 2020065498 A JP2020065498 A JP 2020065498A JP 2020114855 A5 JP2020114855 A5 JP 2020114855A5
Authority
JP
Japan
Prior art keywords
composition
polyethylene oxide
population
permeable
hydrocodone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020065498A
Other languages
English (en)
Japanese (ja)
Other versions
JP6929407B2 (ja
JP2020114855A (ja
Filing date
Publication date
Priority claimed from US14/484,761 external-priority patent/US9132096B1/en
Application filed filed Critical
Publication of JP2020114855A publication Critical patent/JP2020114855A/ja
Publication of JP2020114855A5 publication Critical patent/JP2020114855A5/ja
Application granted granted Critical
Publication of JP6929407B2 publication Critical patent/JP6929407B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020065498A 2014-09-12 2020-04-01 乱用抵抗性医薬組成物 Expired - Fee Related JP6929407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/484,761 US9132096B1 (en) 2014-09-12 2014-09-12 Abuse resistant pharmaceutical compositions
US14/484,761 2014-09-12
JP2017534015A JP6687624B2 (ja) 2014-09-12 2015-09-11 乱用抵抗性医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017534015A Division JP6687624B2 (ja) 2014-09-12 2015-09-11 乱用抵抗性医薬組成物

Publications (3)

Publication Number Publication Date
JP2020114855A JP2020114855A (ja) 2020-07-30
JP2020114855A5 true JP2020114855A5 (OSRAM) 2020-09-24
JP6929407B2 JP6929407B2 (ja) 2021-09-01

Family

ID=54063391

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017534015A Expired - Fee Related JP6687624B2 (ja) 2014-09-12 2015-09-11 乱用抵抗性医薬組成物
JP2020065498A Expired - Fee Related JP6929407B2 (ja) 2014-09-12 2020-04-01 乱用抵抗性医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017534015A Expired - Fee Related JP6687624B2 (ja) 2014-09-12 2015-09-11 乱用抵抗性医薬組成物

Country Status (24)

Country Link
US (6) US9132096B1 (OSRAM)
EP (1) EP3191085B1 (OSRAM)
JP (2) JP6687624B2 (OSRAM)
CN (2) CN107106503B (OSRAM)
AU (2) AU2015313785B2 (OSRAM)
CA (1) CA2870380C (OSRAM)
CR (1) CR20170142A (OSRAM)
CY (1) CY1124757T1 (OSRAM)
DK (1) DK3191085T3 (OSRAM)
ES (1) ES2877058T3 (OSRAM)
HR (1) HRP20210973T1 (OSRAM)
HU (1) HUE054778T2 (OSRAM)
IL (1) IL251011B (OSRAM)
LT (1) LT3191085T (OSRAM)
MX (1) MX380566B (OSRAM)
NZ (1) NZ730882A (OSRAM)
PL (1) PL3191085T3 (OSRAM)
PT (1) PT3191085T (OSRAM)
RS (1) RS62056B1 (OSRAM)
RU (1) RU2764569C2 (OSRAM)
SG (1) SG11201701845XA (OSRAM)
SI (1) SI3191085T1 (OSRAM)
SM (1) SMT202100365T1 (OSRAM)
WO (1) WO2016038584A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132096B1 (en) * 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
JP2020536056A (ja) * 2017-10-02 2020-12-10 パーデュー、ファーマ、リミテッド、パートナーシップ 遅延放出ゲル化剤組成物を含む医薬組成物
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
KR102810926B1 (ko) 2017-12-20 2025-05-22 퍼듀 퍼머 엘피 남용 억제 황산모르핀 제형
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
FI3765525T3 (fi) 2018-03-13 2023-10-16 Zymeworks Bc Inc Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä
CN114105875B (zh) * 2021-12-06 2023-11-03 四川大学 一种吗啡衍生物二氢埃托啡的合成方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4684516A (en) 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5132142A (en) 1991-03-19 1992-07-21 Glatt Gmbh Apparatus and method for producing pellets by layering power onto particles
US5654009A (en) 1991-03-25 1997-08-05 Fujisawa Pharmaceutical Co., Ltd. Delayed action preparation
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US7060293B1 (en) 1994-05-25 2006-06-13 Purdue Pharma Powder-layered oral dosage forms
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
PT914097E (pt) 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
EP1014941B2 (en) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US6709678B2 (en) 1996-08-15 2004-03-23 Losan Pharma Gmbh Easy to swallow oral medicament composition
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
JP3677156B2 (ja) * 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
GB9721746D0 (en) 1997-10-15 1997-12-10 Panos Therapeutics Limited Compositions
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
CA2348871C (en) 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
IT1315274B1 (it) 1999-12-29 2003-02-03 Cip Ninety Two 92 Sa Composizioni farmaceutiche per la somministrazione localizzata nelcavo orale di farmaci antiinfiammatori non stereoidei utili per la
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP1347748A2 (en) 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
CN1592609A (zh) 2001-05-11 2005-03-09 恩德制药公司 抗滥用阿片样物质剂型
AU2002339378A1 (en) 2001-05-22 2002-12-03 Euro-Celtique Compartmentalized dosage form
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
US7968119B2 (en) 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
KR20040060917A (ko) * 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
WO2003013525A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
AU2003220551A1 (en) 2002-03-26 2003-10-13 Euro-Celtique S.A. Sustained-release gel coated compositions
US7300670B2 (en) 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
JP4694207B2 (ja) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル, インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20040091528A1 (en) 2002-11-12 2004-05-13 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
US20060099256A1 (en) 2002-11-27 2006-05-11 Price James C Microspheres and related processes and pharmaceutical compositions
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20090304793A1 (en) 2003-09-22 2009-12-10 Alpharma, Inc. Sustained release opioid formulations and methods of use
EP1663229B1 (en) * 2003-09-25 2010-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
ZA200507017B (en) 2004-02-04 2007-03-28 Foamix Ltd Cosmetic and pharmaceutical foam with solid matter
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP1765292B1 (en) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20060051298A1 (en) * 2004-09-03 2006-03-09 Groenewoud Pieter J Abuse resistent pharmaceutical dosage and method of making same
FR2878161B1 (fr) 2004-11-23 2008-10-31 Flamel Technologies Sa Forme medicamenteuse orale, solide et concue pour eviter le mesusage
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
AU2006298442A1 (en) 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
RU2008113439A (ru) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
WO2007078895A2 (en) * 2005-12-30 2007-07-12 Biovail Laboratories International S.R.L. Modified release formulations of tramadol and uses thereof
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
WO2007096906A2 (en) 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
CA2647360C (en) 2006-03-15 2012-05-15 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2007107787A2 (en) 2006-03-20 2007-09-27 Karrar Ahmad Khan Liquid and solid dosage formulations containing date fruit (phoenix dactylifera)
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
EP2010162A4 (en) 2006-04-03 2013-01-09 Isa Odidi COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2007150075A2 (en) 2006-06-23 2007-12-27 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
KR20090024284A (ko) 2006-06-23 2009-03-06 엘란 파마 인터내셔널 리미티드 나노입자형 나프록센 및 조절 방출형 하이드로코돈을 포함하는 조성물
CA2655596C (en) 2006-06-27 2011-10-25 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8187636B2 (en) * 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
CN101646419A (zh) 2006-11-08 2010-02-10 诺瓦瓦克斯股份有限公司 制备多相药物组合物的固体剂型的方法
WO2008122993A1 (en) 2007-04-09 2008-10-16 Panacea Biotec Limited Controlled release formulation of coated microparticles
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
WO2009076764A1 (en) 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
WO2009114118A2 (en) 2008-03-08 2009-09-17 Theraquest Biosciences, Inc. Oral pharmaceutical compositions of buprenorphine and method of use
TWI519322B (zh) 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
JP5214312B2 (ja) * 2008-04-16 2013-06-19 ホソカワミクロン株式会社 固形製剤およびその製造方法
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
CN102316857A (zh) 2008-12-16 2012-01-11 莱博法姆公司 防止误用的控释配方
ES2607209T3 (es) 2009-02-06 2017-03-29 Egalet Ltd. Composiciones farmacéuticas resistentes al abuso
DK3045043T3 (da) 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
JP5845172B2 (ja) * 2009-05-01 2016-01-20 アデア ファーマスーティカルズ,インコーポレイテッド 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物
EP2477614A2 (en) 2009-09-17 2012-07-25 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CA2784407A1 (en) 2009-12-17 2011-07-14 Cima Labs Inc. Abuse-resistant formulations
US20130022646A1 (en) 2010-02-09 2013-01-24 Rudnic Edward M Controlled Release Formulations of Opioids
US20120321674A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for Preventing Abuse of Solid Dosage Forms
EP2538928B1 (en) 2010-02-24 2017-05-03 Cima Labs Inc. Abuse-resistant formulations
FR2959130A1 (fr) 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
FR2960775A1 (fr) 2010-06-07 2011-12-09 Ethypharm Sa Microgranules resistants au detournement
US8861890B2 (en) 2010-11-24 2014-10-14 Douglas Alan Lefler System and method for assembling and displaying individual images as a continuous image
EP2675436A1 (en) 2011-02-17 2013-12-25 Qrxpharma Limited Technology for preventing abuse of solid dosage forms
KR101619579B1 (ko) 2011-03-25 2016-05-10 퍼듀 퍼머 엘피 제어 방출형 제약 투여 형태
WO2013003622A1 (en) 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
PE20141638A1 (es) * 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
US9065156B2 (en) 2011-08-08 2015-06-23 Wisconsin Alumni Research Foundation Photovoltaic capacitor for direct solar energy conversion and storage
ES2641437T3 (es) 2011-09-16 2017-11-10 Purdue Pharma Lp Formulaciones farmacéuticas resistentes a la manipulación indebida
ES2703688T3 (es) 2011-09-16 2019-03-12 Purdue Pharma Lp Formulaciones de liberación inmediata resistentes a alteración
TW201336529A (zh) * 2011-12-09 2013-09-16 Purdue Pharma Lp 包含聚(ε-己內酯)和聚氧化乙烯之藥物劑量型
TW201722406A (zh) 2012-03-02 2017-07-01 羅德製藥公司 抗破壞性立即釋出型調製劑類
US9549899B2 (en) * 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US10322120B2 (en) 2012-07-31 2019-06-18 Persion Pharmaceuticals Llc Treating pain in patients with hepatic impairment
CA2888278A1 (en) 2012-10-15 2014-04-24 Isa Odidi Oral drug delivery formulations
US9132096B1 (en) * 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Similar Documents

Publication Publication Date Title
ES2260042T3 (es) Formas farmaceuticas de administracion oral que contienen tramadol de liberacion retardada.
RU2201223C2 (ru) Фармацевтическая композиция из множества субъединиц и способ ее получения
JP2934505B2 (ja) 短時間で医薬を放出する投与形態
KR101834033B1 (ko) 주의력 결핍 장애 치료용 고체 경구 제약 조성물
ES2364538T3 (es) Combinación farmacéutica de alisquireno y valsartán.
JP2011504491A (ja) プレガバリンの制御放出医薬組成物
JP2008303223A (ja) 脈動用量薬剤経口送達システム
RU2001132861A (ru) Новый препарат
AU2014270116B2 (en) Transdermal delivery system
RU2244541C2 (ru) Анальгетик с контролируемым высвобождением активного вещества
RO112810B1 (ro) Dispozitiv de eliberare controlata a unui medicament sub forma unei dispersii
US9622979B2 (en) Multilayered dosage form
JP2021516260A (ja) 薬物の時間放出のためのプログラム可能な医薬組成物
RU2015107517A (ru) Фармацевтические композиции мемантина
EP1909770A2 (en) Oral controlled release composition containing levetiracetam
CN101193638A (zh) 用于良性前列腺肥大疗法的组合
CN105338970A (zh) 包含他达拉非和坦洛新的药物胶囊复合制剂
US20150140089A1 (en) Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
JPS59155312A (ja) 新規薬理製剤
RU2011110756A (ru) Фармацевтическая композиция в виде разовой пероральной дозы, содержащая леводопу, карбидопу и энтакапон, или их соли
CN1486686A (zh) 胃漂浮型脉冲释放片
ES2294480T3 (es) Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina.
JP2007510654A (ja) 分極した酸素原子を有するポリマーを含むマトリクスからの正に荷電した薬理学的活性分子の徐放
KR20150044670A (ko) 제어방출되는 프로피온산 계열의 약제학적 조성물
WO2008079102A1 (en) Modified release loxoprofen compositions